A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of VX-121/Tezacaftor/Deutivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
Latest Information Update: 03 Apr 2023
At a glance
- Drugs Deutivacaftor/tezacaftor/vanzacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 29 Mar 2023 Status changed from recruiting to completed.
- 04 Aug 2022 Status changed from not yet recruiting to recruiting.
- 01 Jul 2022 New trial record